BioSpace News Archive

Drug Development

Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Dosing of the first patient expected in the third quarter of 2019

March 26, 2019
·
3 min read
Deals

Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

Compugen Ltd. announced that its entire board of directors and members of management purchased Company shares on the open market during March 2019.

March 26, 2019
·
3 min read
Pharm Country

Industry Roundtable: Home-Based Care Delivers a Positive Impact on Clinical Outcomes and Patient Satisfaction

Industry thought leaders attribute growth in home-based care to convergence of consumerism, value-based care and focus on social determinants

March 26, 2019
·
6 min read
Drug Development

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

IMV Inc., a clinical stage immuno-oncology corporation, announced preliminary data from the phase 2 cohort of the DECIDE clinical study.

March 26, 2019
·
4 min read
Drug Development

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

Conference call with management scheduled for Tuesday March 26 at 8.30 a.m. Eastern time

March 26, 2019
·
10 min read
Business

GT Biopharma Announces Completion of Management Restructuring

Anthony J Cataldo has been named Chairman and Chief Executive Officer.

March 26, 2019
·
6 min read
Deals

MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Fiscal Year 2018 Results, Conference Call and Webcast

MYOS RENS Technology Inc. announced that it will provide financial results for the fourth quarter and fiscal year 2018 on Wednesday, March 27, 2019 after the market closes.

March 26, 2019
·
3 min read
Drug Development

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target

Abcuro, Inc., a biopharmaceutical company developing first-in-class immunomodulatory therapeutics, announced the publication of proof-of-concept data describing KLRG1 as a promising new target for cancer immunotherapy

March 26, 2019
·
1 min read